Allspring Global Investments
CRSP icon

Allspring Global Investments’s CRISPR Therapeutics CRSP Stock Holding History

Allspring Global Investments’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$290K Buy
5,932
+605
+11% +$31.9K ﹤0.01% 1535
2025
Q4 		$286K Buy
+5,327
New +$319K ﹤0.01% 1517
2024
Q3 		– Sell
-31,550
Closed -$1.7M – 2484
2024
Q2 		$1.7M Sell
31,550
-47,374
-60% -$2.74M ﹤0.01% 1208
2024
Q1 		$5.38M Buy
78,924
+41,903
+113% +$3M 0.01% 936
2023
Q4 		$2.32M Sell
37,021
-250,373
-87% -$13.8M ﹤0.01% 1140
2023
Q3 		$13M Sell
287,394
-39,304
-12% -$2.03M 0.02% 675
2023
Q2 		$18.3M Buy
326,698
+17,864
+6% +$1.01M 0.03% 619
2023
Q1 		$14M Buy
308,834
+48,972
+19% +$2.38M 0.02% 696
2022
Q4 		$10.6M Sell
259,862
-9,130
-3% -$484K 0.02% 770
2022
Q3 		$17.6M Sell
268,992
-4,791
-2% -$347K 0.03% 594
2022
Q2 		$16.6M Sell
273,783
-277,781
-50% -$16.3M 0.03% 641
2022
Q1 		$34.6M Buy
551,564
+264,969
+92% +$16.6M 0.04% 499
2021
Q4 		$21.7M Buy
+286,595
New +$25M 0.02% 678

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Allspring Global Investments's CRSP Position: Q1 2026 in Review

Allspring Global Investments increased its CRISPR Therapeutics (CRSP) stake by 11% in Q1 2026, buying an estimated $31.9K and bringing the position to 5,932 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

Allspring Global Investments first reported a position in CRSP in Q4 2021 and has held it in 13 quarters since. The position peaked at $34.6M in Q1 2022. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Allspring Global Investments held 5,932 shares of CRISPR Therapeutics worth $290K as of Q1 2026.
  • Allspring Global Investments bought 605 CRISPR Therapeutics shares in Q1 2026, an estimated $31.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q1 2026, its #1535 holding.
  • Allspring Global Investments first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Allspring Global Investments's CRISPR Therapeutics position peaked at $34.6M in Q1 2022.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Allspring Global Investments's 13F filing for Q1 2026, filed 5 May 2026.